Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer

Oncologist

Volumn 11, Issue 9, 2006, Pages 1010-1017

  Van Cutsem, Eric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cetuximab; Epidermal growth factor receptor; Monoclonal antibody; Panitumumab; Rash; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MATUZUMAB; OXALIPLATIN; PANITUMUMAB; PELITINIB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG TOLERABILITY; HUMAN; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RASH; SKIN ALLERGY; SKIN TOXICITY; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33749847753     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-9-1010     Document Type: Article

References (32)

1. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
2. Rini BI. VEGF-targeted therapy in metastatic renal cell carcinoma. The Oncologist 2005;10:191-197.
3. Harari PM. Epidermal growth factor receptor inhibitor strategies in oncology. Endocr Relat Cancer 2004;11:689-708.
4. Mendelsohn J, Baselga J. Status of epidermal growth factor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.
5. Wells A. Molecules in focus EGF receptor. Int J Biochem Cell Biol 1999;31:637-643.
6. Saltz L, Kies M, Abbruzzese JL et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003;22:204. [Abstract 817].
7. Saltz LB, Meropol NJ, Loehrer PJ Sr. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208.
8. Lenz HJ, Mayer RJ, Gold PJ et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol 2004;22(suppl 14):3510. [Abstract, ASCO Annual Meeting Proceedings (Post-Meeting Ed.)].
9. Hecht JR, Patnaik A, Malik I et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. J Clin Oncol 2004;22(suppl 14):3511. [Abstract, ASCO Annual Meeting Proceedings (Post-Meeting Ed.)].
10. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
11. Rosenberg AH, Loehrer PJ, Needle MN et al. Erbitux (IMC-C225) plus weekly irinotecan (CPT-11), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002;21:536a.
12. Folprecht G, Lutz M, Schoeffski P et al. Cetuximab/irinotecan/high-dose- 5-fluorouracil/leucovorin (HD-5-FU/LV) in the first-line therapy of metastatic colorectal cancer (CRC). 2004 Gastrointestinal Cancers Symposium. 283a.
13. Rougier P, Raoul J-L, Van Laethem J-L et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. J Clin Oncol 2004;22(suppl 14):3513. [Abstract. ASCO Annual Meeting Proceedings (Post-Meeting Ed.)].
14. Van Cutsem E, Tabernero J, Diaz-Rubio E et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Ann Oncol 2004;15(suppl 3):iii91. 339a.
15. Höhler T, Dittrich C, Lordick F, et al. A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR): preliminary results. Ann Oncol 2004; 15(suppl 3):2620a.
16. Berlin J, Malik I, Picus J et al. Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mCRC). Ann Oncol 2004;15 suppl 3:Abstract 265PD.
17. Jung YD, Mansfield PF, Akagi M et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-1140.
18. Ciardiello F, Bianco R, Damiano V et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-3747.
19. Saltz LB, Lenz H, Kindler H et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. 2005 Gastrointestinal Cancers Symposium. Abstract 169b.
20. Saltz LB, Lenz H, Hochster H et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. 2005 ASCO Annual Meeting. 3508a.
21. Saltz L, Rubin M, Hochster H et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002;21:7a.
22. Xiong HQ, Rosenberg A, LoBuglio A et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-2616.
23. Kies MS, Arquette MA, Nabell L et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 2002;21:925a.
24. Van Cutsem E, Mayer R, Gold P et al. Correlation of acne rash and tumor response with cetuximab monotherapy in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Eur J Cancer 2004;(suppl 2):85-86. 279a.
25. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-1433.
26. Scartozzi M, Bearzi I, Berardi R et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772-4778.
27. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810.
28. Mackenzie MJ, Hirte HW, Glenwood G et al. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest New Drugs 2005;23:165-170.
29. Rothenberg M, Lafleur B, Washington MK et al. Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): An Eastern Cooperative Oncology Group study. J Clin Oncol 2004;22(suppl 14):3000. [Abstract, ASCO Annual Meeting Proceedings (Post-Meeting Ed.)].
30. Cho CD, Fisher GA, Halsey J et al. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Invest New Drugs 2005;Jul 18:[Epub ahead of print].
31. Van Cutsem E, Beale P, Delord J et al. Tarceva (erlotinib) in combination with Xeloda and oxaliplatin in patients with metastatic colorectal cancer (CRC). A phase I dose escalation trial. Clin Cancer Res 2003;9:109a.
32. Tejpar S, Van Cutsem E, Gamelin E et al. Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). J Clin Oncol 2004;22(suppl 14):3579. [Abstract, ASCO Annual Meeting Proceedings (Post-Meeting Ed.)].